Action TVGN TEVOGEN BIO HOLDINGS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Tevogen Bio Holdings Inc.

Actions

TVGN

US88165K1016

Temps Différé Nasdaq
Autres places de cotation
 20:00:41 20/06/2024 		Varia. 5j. Varia. 1 janv.
0,7745 USD -2,91 % Graphique intraday de Tevogen Bio Holdings Inc. -11,80 % -93,04 %
06/06 Tevogen Bio confirme l'efficacité continue du Tvgn 489, son immunothérapie allogénique expérimentale sur étagère, contre les souches dominantes de Sars-CoV-2. CI
13/05 Les investisseurs attendent des données clés sur l'inflation dans les jours à venir, alors que les contrats à terme américains tendent vers une hausse modeste lundi MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
Tevogen Bio Set to Join Russell 3000® Index
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Tevogen Bio Confirms Ongoing Efficacy of Tvgn 489, Its Investigational Allogeneic Off-The-Shelf Immunotherapy, Against Dominant Flirt Strains of Sars-Cov-2
Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
Top Premarket Gainers
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Sector Update: Health Care Stocks Higher in Afternoon Trading
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Top Premarket Gainers
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Top Premarket Gainers
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TVGN
  4. Actualités Tevogen Bio Holdings Inc.
  5. Autres langues